Report cover image

Global Peptide Receptor Radionuclide Therapy (PRRT) Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 198 Pages
SKU # APRC20561391

Description

Summary

According to APO Research, The global Peptide Receptor Radionuclide Therapy (PRRT) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Peptide Receptor Radionuclide Therapy (PRRT) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Peptide Receptor Radionuclide Therapy (PRRT) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Peptide Receptor Radionuclide Therapy (PRRT) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Peptide Receptor Radionuclide Therapy (PRRT) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Peptide Receptor Radionuclide Therapy (PRRT) include Aurobindo Pharma, Curium Pharmaceuticals, Lantheus, Mundipharma, Bayer and Novartis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes


This report presents an overview of global market for Peptide Receptor Radionuclide Therapy (PRRT), market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Peptide Receptor Radionuclide Therapy (PRRT), also provides the revenue of main regions and countries. Of the upcoming market potential for Peptide Receptor Radionuclide Therapy (PRRT), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peptide Receptor Radionuclide Therapy (PRRT) revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Peptide Receptor Radionuclide Therapy (PRRT) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Peptide Receptor Radionuclide Therapy (PRRT) revenue, projected growth trends, production technology, application and end-user industry.

Peptide Receptor Radionuclide Therapy (PRRT) Segment by Company

Aurobindo Pharma
Curium Pharmaceuticals
Lantheus
Mundipharma
Bayer
Novartis
Peptide Receptor Radionuclide Therapy (PRRT) Segment by Type

Midgut Neuroendocrine Tumor
Gastroenteropancreatic Neuroendocrine Tumor
Foregut Neuroendocrine Tumor
Hindgut Neuroendocrine Tumor
Peptide Receptor Radionuclide Therapy (PRRT) Segment by Application

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Peptide Receptor Radionuclide Therapy (PRRT) Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Receptor Radionuclide Therapy (PRRT) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Receptor Radionuclide Therapy (PRRT) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Receptor Radionuclide Therapy (PRRT).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Peptide Receptor Radionuclide Therapy (PRRT) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Peptide Receptor Radionuclide Therapy (PRRT) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide Receptor Radionuclide Therapy (PRRT) revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

198 Pages
1 Market Overview
1.1 Product Definition
1.2 Peptide Receptor Radionuclide Therapy (PRRT) Market by Type
1.2.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Midgut Neuroendocrine Tumor
1.2.3 Gastroenteropancreatic Neuroendocrine Tumor
1.2.4 Foregut Neuroendocrine Tumor
1.2.5 Hindgut Neuroendocrine Tumor
1.3 Peptide Receptor Radionuclide Therapy (PRRT) Market by Application
1.3.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Online Pharmacies
1.3.4 Retail Pharmacies
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Peptide Receptor Radionuclide Therapy (PRRT) Market Dynamics
2.1 Peptide Receptor Radionuclide Therapy (PRRT) Industry Trends
2.2 Peptide Receptor Radionuclide Therapy (PRRT) Industry Drivers
2.3 Peptide Receptor Radionuclide Therapy (PRRT) Industry Opportunities and Challenges
2.4 Peptide Receptor Radionuclide Therapy (PRRT) Industry Restraints
3 Global Growth Perspective
3.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Perspective (2020-2031)
3.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Growth Trends by Region
3.2.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Region (2020-2025)
3.2.3 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Players
4.1.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Players (2020-2025)
4.1.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue Market Share by Players (2020-2025)
4.1.3 Global Peptide Receptor Radionuclide Therapy (PRRT) Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Peptide Receptor Radionuclide Therapy (PRRT) Key Players Headquarters & Area Served
4.4 Global Peptide Receptor Radionuclide Therapy (PRRT) Players, Product Type & Application
4.5 Global Peptide Receptor Radionuclide Therapy (PRRT) Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Market CR5 and HHI
4.6.3 2024 Peptide Receptor Radionuclide Therapy (PRRT) Tier 1, Tier 2, and Tier 3
5 Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Type
5.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2020-2031)
5.3 Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue Market Share by Type (2020-2031)
6 Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Application
6.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2020-2031)
6.3 Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Aurobindo Pharma
7.1.1 Aurobindo Pharma Comapny Information
7.1.2 Aurobindo Pharma Business Overview
7.1.3 Aurobindo Pharma Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (2020-2025)
7.1.4 Aurobindo Pharma Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
7.1.5 Aurobindo Pharma Recent Developments
7.2 Curium Pharmaceuticals
7.2.1 Curium Pharmaceuticals Comapny Information
7.2.2 Curium Pharmaceuticals Business Overview
7.2.3 Curium Pharmaceuticals Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (2020-2025)
7.2.4 Curium Pharmaceuticals Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
7.2.5 Curium Pharmaceuticals Recent Developments
7.3 Lantheus
7.3.1 Lantheus Comapny Information
7.3.2 Lantheus Business Overview
7.3.3 Lantheus Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (2020-2025)
7.3.4 Lantheus Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
7.3.5 Lantheus Recent Developments
7.4 Mundipharma
7.4.1 Mundipharma Comapny Information
7.4.2 Mundipharma Business Overview
7.4.3 Mundipharma Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (2020-2025)
7.4.4 Mundipharma Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
7.4.5 Mundipharma Recent Developments
7.5 Bayer
7.5.1 Bayer Comapny Information
7.5.2 Bayer Business Overview
7.5.3 Bayer Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (2020-2025)
7.5.4 Bayer Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
7.5.5 Bayer Recent Developments
7.6 Novartis
7.6.1 Novartis Comapny Information
7.6.2 Novartis Business Overview
7.6.3 Novartis Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (2020-2025)
7.6.4 Novartis Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
7.6.5 Novartis Recent Developments
8 North America
8.1 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue (2020-2031)
8.2 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2020-2031)
8.2.1 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2020-2025)
8.2.2 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2026-2031)
8.3 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Type (2020-2031)
8.4 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2020-2031)
8.4.1 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2020-2025)
8.4.2 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2026-2031)
8.5 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Application (2020-2031)
8.6 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country
8.6.1 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2020-2025)
8.6.3 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
8.6.6 Mexico
9 Europe
9.1 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue (2020-2031)
9.2 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2020-2031)
9.2.1 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2020-2025)
9.2.2 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2026-2031)
9.3 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Type (2020-2031)
9.4 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2020-2031)
9.4.1 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2020-2025)
9.4.2 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2026-2031)
9.5 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Application (2020-2031)
9.6 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country
9.6.1 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2020-2025)
9.6.3 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
9.6.9 Spain
9.6.10 Netherlands
9.6.11 Switzerland
9.6.12 Sweden
9.6.13 Poland
10 China
10.1 China Peptide Receptor Radionuclide Therapy (PRRT) Revenue (2020-2031)
10.2 China Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2020-2031)
10.2.1 China Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2020-2025)
10.2.2 China Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2026-2031)
10.3 China Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Type (2020-2031)
10.4 China Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2020-2031)
10.4.1 China Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2020-2025)
10.4.2 China Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2026-2031)
10.5 China Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue (2020-2031)
11.2 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2020-2031)
11.2.1 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2020-2025)
11.2.2 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2026-2031)
11.3 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Type (2020-2031)
11.4 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2020-2031)
11.4.1 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2020-2025)
11.4.2 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2026-2031)
11.5 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Application (2020-2031)
11.6 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country
11.6.1 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2020-2025)
11.6.3 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue (2020-2031)
12.2 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2020-2031)
12.2.1 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2020-2025)
12.2.2 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2026-2031)
12.3 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Type (2020-2031)
12.4 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2020-2031)
12.4.1 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2020-2025)
12.4.2 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2026-2031)
12.5 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Application (2020-2031)
12.6 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country
12.6.1 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2020-2025)
12.6.3 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.